ImmunoGen Message Board - Msg: 14819055

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ImmunoGen

IMGN 31.23

0.0%

Feb 26 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: RJMC who wrote (3707)	11/15/2000 7:57:43 PM
From: Chi Wong	Read Replies (1) of 5665

I agree with everything that RJ has stated. Mitch indicated that a deal or deals will be structured as a TAP technology swap for antibody targets. He also indicated that many companies are currently evaluating the technology ie IMGN puts a tap on someone's antibody target and gives it back to them for evaluation. 2 things that stand out for me is Mitch saying anyone who's ever done a deal with genentech knows how grueling their due diligence procedures are and the sbh deal was done on preclinicals alone months before the ind was filed. dna deals are single digit royalties, sbh double digit. Milestone pmts are structured for cash flow and there is no front/backend loading.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next